The CAR scFv confers the ability to T cells to directly recognize cancer antigens independent of MHC antigen presentation, and CAR specific recognition/binding to tumor antigen drives CAR T cell activation and tumor cell killing (23, 24). Here, HLA-C is linked to neoplasm.